Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 681

1.

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.

Block GA, Hulbert-Shearon TE, Levin NW, Port FK.

Am J Kidney Dis. 1998 Apr;31(4):607-17.

PMID:
9531176
2.

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM.

J Am Soc Nephrol. 2004 Aug;15(8):2208-18.

4.

Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients.

Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK.

J Am Soc Nephrol. 2001 Oct;12(10):2131-8.

5.

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK.

Am J Kidney Dis. 2008 Sep;52(3):519-30. doi: 10.1053/j.ajkd.2008.03.020. Epub 2008 Jun 2.

PMID:
18514987
6.

Phosphorus control in peritoneal dialysis patients.

Yavuz A, Ersoy FF, Passadakis PS, Tam P, Evaggelos DM, Katopodis KP, Ozener C, Akçiçek F, Camsari T, Ateş K, Ataman R, Vlachojannis GJ, Dombros NA, Utaş C, Akpolat T, Bozfakioğlu S, Wu G, Karayaylali I, Arinsoy T, Stathakis CP, Yavuz M, Tsakiris DJ, Dimitriades AC, Yilmaz ME, Gültekin M, Süleymanlar G, Oreopoulos DG.

Kidney Int Suppl. 2008 Apr;(108):S152-8. doi: 10.1038/sj.ki.5002617.

PMID:
18379539
7.

Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.

Fukagawa M, Kido R, Komaba H, Onishi Y, Yamaguchi T, Hasegawa T, Kurita N, Fukuma S, Akizawa T, Fukuhara S.

Am J Kidney Dis. 2014 Jun;63(6):979-87. doi: 10.1053/j.ajkd.2013.08.011. Epub 2013 Oct 8.

PMID:
24119541
8.

Mild hyperphosphatemia and mortality in hemodialysis patients.

Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P.

Am J Kidney Dis. 2005 Jul;46(1):68-77.

PMID:
15983959
9.

Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.

Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernández-Martín JL, Rodríguez-Puyol D, Cannata-Andía JB.

Nephrol Dial Transplant. 2011 Jun;26(6):1938-47. doi: 10.1093/ndt/gfq304. Epub 2010 May 31.

PMID:
20513773
10.

A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients.

Movilli E, Feliciani A, Camerini C, Brunori G, Zubani R, Scolari F, Parrinello G, Cancarini GC.

Nephron Clin Pract. 2005;101(4):c161-7. Epub 2005 Aug 9.

PMID:
16103720
11.

Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access.

Lacson E Jr, Wang W, Hakim RM, Teng M, Lazarus JM.

Am J Kidney Dis. 2009 Jan;53(1):79-90. doi: 10.1053/j.ajkd.2008.07.031. Epub 2008 Oct 18.

PMID:
18930570
12.

The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients.

Phelan PJ, O'Kelly P, Walshe JJ, Conlon PJ.

Ren Fail. 2008;30(4):423-9. doi: 10.1080/08860220801964236.

PMID:
18569917
13.

Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.

Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM.

Adv Ren Replace Ther. 2003 Apr;10(2):133-45.

PMID:
12879374
14.

Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.

Lorenzo Sellares V, Torres Ramírez A.

Drugs Aging. 2004;21(3):153-65. Review.

PMID:
14979734
15.
16.

Hypocalcemia, morbidity, and mortality in end-stage renal disease.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O'Dea R, Murray DC, Barre PE.

Am J Nephrol. 1996;16(5):386-93.

PMID:
8886175
17.

Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.

Gadallah MF, el-Shahawy M, Andrews G, Ibrahim M, Ramdeen G, Hanna D, Gorospe W, Morkos A, Abbassian M, Moles K.

Adv Perit Dial. 2001;17:29-36.

PMID:
11510292
18.

Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD).

Qunibi WY.

Kidney Int Suppl. 2004 Sep;(90):S8-S12. Review.

PMID:
15296501
20.

Adherence to treatment and hospitalization risk in hemodialysis patients.

Vaiciuniene R, Kuzminskis V, Ziginskiene E, Skarupskiene I, Bumblyte IA.

J Nephrol. 2012 Sep-Oct;25(5):672-8. doi: 10.5301/jn.5000038.

PMID:
21983989

Supplemental Content

Support Center